On May 27, Kelun-Biotech Biopharmaceutical rose 3.07% in regular trading, trading at 477.8 HKD/share, with trading volume of approximately 130 million HKD.

On the news front, Nomura recently raised the company's target price from HK$438.3 to HK$544.42 and maintained a \"Buy\" rating. The broker cited encouraging Phase III data for the company's TROP2 ADC drug sac-TMT combined with pembrolizumab for first-line treatment of PD-L1 positive non-small cell lung cancer, noting a PFS hazard ratio of 0.35 and a positive OS trend with HR of 0.55. This marks the first ADC drug globally to demonstrate PFS improvement in a Phase III trial for this indication. The target price upgrade also reflects an improved terminal growth rate assumption raised from 4% to 4.5% based on enhanced sales prospects.

Additionally, multiple registration studies have been selected for oral presentation at the upcoming ASCO annual meeting, with pipeline global value realization expectations continuing to catalyze share price performance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)